"Matou te fiafia e faʻafeiloaʻi le CEQUA o se togafitiga fou mo le sili atu ma le ono miliona tagata Kanata o loʻo nonofo ma faʻamaʻi mata mama1," o le tala lea a Abhay Gandhi, Pule Sili North America, Sun Pharma. "O lenei faʻalauiloa o se mea taua tele mo Sun Pharma aʻo matou faʻalauteleina a matou faʻailoga mata i Kanata ma faʻaalia ai la matou tautinoga i le tuʻuina atu o vailaʻau fou e lagolago ai maʻi ma fomaʻi filifiliga."

I le faaopoopo atu i lona taatele muamua i tagata Kanata, o se lipoti talu ai nei mai le Center for Ocular Research & Education (CORE) ua faʻaalia ai o le maualuga o faʻamaʻi mata mago o loʻo faʻatupulaʻia ona o le faʻateleina o le ofuina o matapulepule, lea e mafai ona oʻo atu ai i faʻamago i luga. luga ole mata.2

"Matou te fiafia e vaʻai i se oloa fou o loʻo avanoa nei i le toʻatele o tagata Kanata o loʻo mafatia i le keratoconjunctivitis sicca poʻo le faʻamaʻi mata mama," o le tala lea a W. Bruce Jackson, MD, sa avea muamua ma Polofesa ma Taitaifono, Matagaluega o Ophthalmology, McGill University ma le Iunivesite o Ottawa. "CEQUA, faʻatasi ai ma ana tekinolosi nanomicellar ma faʻateleina le malosi o le cyclosporine, e mafai ona avea ma se faʻaopoopoga taua i a tatou filifiliga togafitiga aʻo taumafai tagata tomai faapitoa i mata mo togafitiga faʻapitoa."

OA MEA E AVEA MAI LENEI TUSI:

Education (CORE) has shown that rates of dry eye disease are on the rise due to an increase in mask wearing, which can lead to dry spots on the ocular surface.
“This launch is an important milestone for Sun Pharma as we expand our ophthalmics portfolio into Canada and it demonstrates our commitment to providing innovative medicines to support patient and physician choice.
“We are delighted to see a new product now available to the many Canadians suffering from keratoconjunctivitis sicca or dry eye disease,”.